The present application relates to a novel promoter and a method for producing a desired substance using the same.

Microorganisms are provided, such as lactic acid bacteria (e.g., Lactococcus lactis) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a CeD-specific antigen (e.g., a gliadin polypeptide comprising at least one HLA-DQ2 specific epitope, at least one deamidated HLA-DQ2 specific epitope, at least one HLA-DQ8 specific epitope, at least one deamidated HLA-DQ8 specific epitope, or a combination of (a) at least one HLA-DQ2-specific epitope and/or at least one deamidated HLA-DQ2 specific epitope, and (b) at least one HLA-DQ8 specific epitope and/or at least one deamidated HLA-DQ8 specific epitope) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. Compositions (e.g., pharmaceutical compositions), methods of using the microorganisms and compositions are provided, e.g., for the treatment of celiac disease (CeD). The microorganism may be administered orally, delivering the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides.

An allulose 3-epimerase mutant, a genetically engineered bacterium expressing the mutant, and an immobilized allulose 3-epimerase enzyme and an immobilization method thereof are described. A high-throughput screening method is used to obtain an allulose 3-epimerase mutant efficiently expressed in a fermentation process, which can catalyze efficient conversion of fructose to D-allulose, providing an efficient production path for key enzymes required in a D-allulose production process. Additionally, the allulose 3-epimerase is bonded to an immobilizing resin to prepare an immobilized allulose 3-epimerase enzyme. The immobilized enzyme can be applied to batch or continuous reactions to catalyze efficient conversion of fructose to D-allulose.

Described herein are genetically-engineered organisms comprising synthetic operons for the production of isoprenoids, carotenoids, and retinoids, optimized for use in a hydrocarbonoclastic organism, and methods for the synthesis and extraction of isoprenoids in a biofilm bioreactor comprising the genetically-engineered organisms.

A cofactor self-sufficient Escherichia coli and its construction method and application in the synthesis of L-glufosinate are provided. The present invention expresses a NADH kinase and key enzymes of the cofactor synthesis pathway in E. coli, and knocks out the genes of enzymes that catabolizes cofactor, and with the addition of co-metabolic intermediates during cell incubation, the intracellular NADP(H) concentration is increased by at least 50% and the catalytic activity of glutamate dehydrogenase by 2-fold, resulting in a significant increase in the spatiotemporal yield of the-glufosinate synthesis reaction.

The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.

This disclosure relates to genetically engineered microorganisms for overexpressing microcin compositions, e.g., MccH47 compositions and MccI47 compositions, which are post-translationally modified with a covalent linkage at the C-terminus to a siderophore, such as mono-glycosylated cyclic enterobactin (MGE), to form microcin-MGE compositions, e.g., MccH47-MGE and MccI47-MGE compositions, the purified compositions themselves, methods of making the purified compositions, and methods of using the purified compositions to treat or reduce the risk of bacterial infections or dysbiosis.

The present invention relates to the metabolic engineering of a microbial host for the synthesis of value-added products from oil palm empty fruit brunches (OPEFBs). In one embodiment, the genetically engineered microorganism is Escherichia coli comprising a metabolic pathway consisting of 9 enzymes (11 genes) to utilize depolymerized lignin, namely vanillin, p-coumaric acid, p-hydroxybenzaldehyde, vanillic acid, p-hydroxybenzoic acid and ferulic acid, to produce β-ketoadipic acid, which can be subsequently converted into commercially important derivatives such as adipic acid and levulinic acid. The enzymes are feruloyl-CoA synthetase (fcs), enoyl-CoA hydratase (ech), vanillin dehydrogenase (vdh), vanillate O-demethylase (vanA; vanA and vanB), p-hydroxy benzoate hydroxylase (pobA), protocatechuate 3,4-dioxygenase {pcaGH; pcaG and pcaH), 3-carboxy-cis, cis-muconate cycloisomerase (pcaB), 4-carboxymuconolactone decarboxylase (pcaC), and β-ketoadipate enol-lactone hydrolase (pcaD).

Aspects of the disclosure relate to biosynthesis of histidine in host cells. For example, host cells may comprise: a promoter; a ribosome binding site (RBS); and a nucleic acid comprising: hisG; hisD; hisC hisB; hisH; hisA; hisF; and/or hisI. Host cells may further comprise a nucleic acid encoding a ribose phosphate pyrophosphokinase (RPPK), optionally comprising one or more amino acid substitutions relative to the sequence of wildtype E. coli RPPK. Host cells of the disclosure may comprise a nucleic acid encoding a 5,10-methylene-tetrahydrofolate dehydrogenase/5,10-methylene-tetrahydrofolate cyclohydrolase (MTHFDC) enzyme. Further aspects of the disclosure relate to production of purine pathway metabolites and/or plasmid DNA in host cells.

Provided are a xanthine amide hydrolase and the use thereof, particularly the use thereof for treating gout.